Bristol-Myers Squibb Company (BMY)
| Market Cap | 90.69B |
| Revenue (ttm) | 45.53B |
| Net Income (ttm) | -6.15B |
| Shares Out | 2.03B |
| EPS (ttm) | -3.10 |
| PE Ratio | n/a |
| Forward PE | 6.23 |
| Dividend | $2.40 (5.36%) |
| Ex-Dividend Date | Apr 4, 2024 |
| Volume | 10,618,108 |
| Open | 43.56 |
| Previous Close | 43.67 |
| Day's Range | 43.50 - 44.81 |
| 52-Week Range | 43.33 - 69.10 |
| Beta | 0.39 |
| Analysts | Hold |
| Price Target | 59.56 (+33.13%) |
| Earnings Date | Apr 25, 2024 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $59.56, which is an increase of 33.13% from the latest price.
News
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Upcoming Investor Conferences.
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CRC--European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line.
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BLA--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase).
Should You Pick Bristol Myers Squibb Stock At $45?
Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an adju...
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb
AMSTERDAM--(BUSINESS WIRE)--Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol My...
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S ...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb's world-leading expert...
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine.
Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts
The pharmaceutical company is implementing an initiative to cut costs by $1.5 billion by 2025 that will include about 2,200 job cuts.
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates
Bristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by strong sales of its top-selling blood thinner Eliquis. The drugmaker reported a net loss of $11.911 ...
Bristol Myers posts quarterly loss, revenue rises 5%
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2024.
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies
Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients.
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $BMY #CART--Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufactur...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY). Such investors ar...
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AACR--KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with.
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain...
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT4--BMS Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia.
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT--Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT.
U.S. FDA allows expanded use of Bristol Myers' cell therapy
The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer.
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #CART--U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma.
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.
European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
PRINCETON N.J.--(BUSINESS WIRE)---- $BMY #COMMANDS--European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent.